Health Condition 1: C61- Malignant neoplasm of prostate
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male patients = 18 years of age OR legal age of being an adult in the country as per local regulations 2. Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations 3. Patients with a diagnosis of metastatic (stage IV) mCRPC, confirmed by either biopsy of a metastatic tumour site, or by history of biopsy-proven localized disease and evidence of metastatic disease on imaging studies (which is clearly noted in hospital/clinical records) and progression on ADT alone between 01 January 2016 and 31 December 2018 4. Availability of medical records at the participating site reflecting at least one LOT received and at least 12 months of follow-up from the index date (unless the patient died/lost to follow-up within the first 12 months after diagnosis)
Exclusion criteria
Exclusion criteria: 1. Patients with a concomitant cancer at the time of diagnosis of mCRPC or those who are treated with any anti-cancer therapy indicated for other cancers within 6 months of diagnosis of mCRPC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms. 2. Patients unable to give an informed consent (unless a waiver is granted)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the real-world treatment patterns in patients with mCRPCTimepoint: one time | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the demographic and clinico-pathological characteristics of patients diagnosed with mCRPC To determine the survival outcomes associated with different treatment regimens used for mCRPC To assess the real-world effectiveness (including real-world progression-free survival [rwPFS] and real-world response rate [rwRR]) of different treatment regimens used for mCRPC To characterize BRCA1/2 and HRRm status in patients with mCRPC, if availableTimepoint: one time | — |
Countries
Argentina, Brazil, Chile, Colombia, Egypt, India, Malaysia, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Contacts
Public ContactMr Amit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed